Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 11/20 | 0.63 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.63 |
| ▸ | DPP9 | Q86TI2 | 8/20 | 0.58 |
| ▸ | DPP8 | Q6V1X1 | 8/20 | 0.58 |
| ▸ | DPP4 | P27487 | 5/20 | 0.58 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.50 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.50 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.50 |
| ▸ | RRM1 | P23921 | 1/20 | 0.49 |
| ▸ | METAP1 | P53582 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.47 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.46 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.46 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15186165 | 1.00 | DPP7 (0.63) | DPP7SLC15A1DPP9DPP8DPP4 | |
| SCHEMBL8231118 | 0.94 | DPP7 (0.61) | DPP7SLC15A1DPP9DPP8DPP4 | |
| SCHEMBL13311872 | 0.94 | DPP7 (0.61) | DPP7SLC15A1DPP9DPP8DPP4 | |
| SCHEMBL12413912 | 0.92 | GNAI3 (0.60) | DPP7SLC15A1DPP9DPP8DPP4 | |
| SCHEMBL13350890 | 0.92 | GNAI3 (0.60) | DPP7SLC15A1DPP9DPP8DPP4 | |
| SCHEMBL13351302 | 0.92 | GNAI3 (0.60) | DPP7SLC15A1DPP9DPP8DPP4 | |
| SCHEMBL8403553 | 0.89 | DPP7 (0.48) | DPP7SLC15A1DPP9DPP8DPP4 | |
| SCHEMBL2420401 | 0.86 | — | — | |
| SCHEMBL15186164 | 0.86 | — | — | |
| SCHEMBL14456838 | 0.83 | DPP7 (0.51) | DPP7SLC15A1DPP9DPP8DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011149995-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA [C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2011-12-01 | — | — | WO | claimed |
| US-20220194930-A1 | Matrix Metalloproteinase Inhibitors and Imaging Agents, And Methods Using Same | UNIV YALE (US) | 2022-06-23 | — | — | US | disclosed |
| US-8637550-B2 | Heteroaryl diamide compounds useful as MMP-13 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-28 | — | — | US | disclosed |
| WO-2011149995-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA [C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2011-12-01 | — | — | WO | disclosed |
| WO-2010062927-A2 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA(C)PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-06-03 | — | — | WO | disclosed |
| WO-2010022249-A2 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | ENSEMBLE DISCOVERY CORPORATION (US) | 2010-02-25 | — | — | WO | disclosed |
| US-20060223761-A1 | Methods and compounds for inhibiting beta-amyloid peptide release and/or its synthesis | ELAN PHARMACEUTICALS, INC. (US) | 2006-10-05 | — | — | US | disclosed |
| US-6888022-B2 | Methods and compounds for inhibiting β-amyloid peptide release and/or its synthesis | ATHENA NEUROSCIENCES, INC. (US) | 2005-05-03 | — | — | US | disclosed |
| US-6861558-B2 | Methods and compounds for inhibiting β-amyloid peptide release and/or its synthesis | ELAN PHARMACEUTICALS, INC. (US) | 2005-03-01 | — | — | US | disclosed |
| US-20030229024-A1 | Methods and compounds for inhibiting beta-amyloid peptide release and/or its synthesis | AUDIA JAMES E (US) | 2003-12-11 | — | — | US | disclosed |
| US-20010020097-A1 | N-(ARYL/HETEROARYL) AMINO ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS | AUDIA JAMES E (US) | 2001-09-06 | — | — | US | disclosed |
| US-6211235-B1 | ALZHEIMERS DISEASE | ELAN PHARMACEUTICALS, INC. | 2001-04-03 | — | — | US | disclosed |
| US-6207710-B1 | FOR THERAPY OF ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. | 2001-03-27 | — | — | US | disclosed |
| US-6191166-B1 | ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. | 2001-02-20 | — | — | US | disclosed |
| US-6096782-A | N-(aryl/heteroaryl) amino acid derivatives pharmaceutical compositions comprising same and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds | ATHENA NEUROSCIENCES, INC. (US) | 2000-08-01 | — | — | US | disclosed |
| EP-0942924-A2 | METHODS AND COMPOUNDS FOR INHIBITING $g(b)-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS | Elan Pharmaceuticals, Inc. (US) | 1999-09-22 | — | — | EP | disclosed |
| EP-0942923-A2 | N-(ARYL/HETEROARYL) AMINO ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING $g(b)-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS | Elan Pharmaceuticals, Inc. (US) | 1999-09-22 | — | — | EP | disclosed |
| WO-1998022494-A9 | METHODS AND COMPOUNDS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR SYNTHESIS | — | 1998-08-20 | — | — | WO | disclosed |
| WO-1998022494-A2 | METHODS AND COMPOUNDS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR SYNTHESIS | ELAN PHARMACEUTICALS, INC. (US) | 1998-05-28 | — | — | WO | disclosed |
| WO-1998022493-A2 | N-(ARYL/HETEROARYL) AMINO ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS | ELAN PHARMACEUTICALS, INC. (US) | 1998-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223761-A1 | Methods and compounds for inhibiting beta-amyloid peptide release and/or its synthesis | APP, BACE1, IAPP | DPP7 110/4885SLC15A1 2190/4885DPP9 199/4885 |
| US-20030229024-A1 | Methods and compounds for inhibiting beta-amyloid peptide release and/or its synthesis | APP, BACE1, IAPP | DPP7 110/4885SLC15A1 2070/4885DPP9 205/4885 |
| US-20010020097-A1 | N-(ARYL/HETEROARYL) AMINO ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS | APP, BACE1, IAPP | DPP7 118/4885SLC15A1 894/4885DPP9 119/4885 |
| US-20220194930-A1 | Matrix Metalloproteinase Inhibitors and Imaging Agents, And Methods Using Same | MMP3, MMP1, MMP10 | DPP7 143/4885SLC15A1 800/4885DPP9 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.